A drug that's been found to slow the progress of Alzheimer's disease by clearing proteins in the brain has been approved for use in Australia.The Therapeutic Goods Administration (TGA) has approved a drug called Donanemab for those with mild cognitive impairment or mild dementia due to Alzheimer's disease.

The very first blood test for Alzheimer's disease detection has been green-lit by the US Food and Drug Administration (FDA), providing a simpler and less invasive method for early diagnosis and speedier intervention.

The Food and Drug Administration cleared a new kind of test for Alzheimer’s disease designed to be more accessible and less risky for patients with cognitive decline.